<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478698</url>
  </required_header>
  <id_info>
    <org_study_id>tPADNase 1</org_study_id>
    <nct_id>NCT01478698</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients</brief_title>
  <official_title>A Phase 1, Open Label, Non Randomised Safety Trial of Intraperitoneal tPA and DNase in Peritoneal Dialysis Patients With Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Charles Gairdner Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sir Charles Gairdner Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Intraperitoneal tPA and DNase is well tolerated at a number of different doses. Different
      doses of tPA and DNase will have a dose-related effect on inflammatory markers (CRP and
      intraperitoneal white cell count).

      Aims:

        1. To examine the tolerability of different doses of intraperitoneal tPA and DNase compared
           to standard treatment.

        2. To examine the changes in biochemical and clinical outcomes of PD Peritonitis with the
           addition of intraperitoneal tPA and DNase to usual therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>72 hours</time_frame>
    <description>Participants will be examined for potential adverse reactions during this trial, including - pain; abnormalities in systemic coagulation profile; bleeding; and altered blood pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers of inflammation</measure>
    <time_frame>21 days</time_frame>
    <description>Biochemical markers of inflammation will be measured on days 1, 3, 5, 7, 14 and 21, including - c-reactive protein, white cell count, dialysate white cell count, procalcitonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical markers of inflammation</measure>
    <time_frame>21 days</time_frame>
    <description>pain score; days till pain free; proportion requiring catheter removal; days of hospitalisation; days of fever (temperature &gt; 37.0 degrees on at least one occasion)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Additional variables</measure>
    <time_frame>3 months</time_frame>
    <description>gentamycin and vancomycin levels, ultrafiltration volume; mortality; relapse and recurrence rates of peritonitis</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <condition>Peritoneal Dialysis, Continuous Ambulatory</condition>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator (tPA)</intervention_name>
    <description>tPA 10mg per dose intraperitoneal</description>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_label>2 doses</arm_group_label>
    <arm_group_label>4 doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant deoxyribonuclease (DNase)</intervention_name>
    <description>DNase 5mg per dose given intraperitoneally.</description>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_label>2 doses</arm_group_label>
    <arm_group_label>4 doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PD patient

          2. Proven peritonitis (as defined as at least 2 of: (i) Symptoms and/or signs of
             peritonitis; (ii) Cloudy dialysate OR dialysate white cell count &gt; 100x 106/L with
             &gt;50% neutrophils; (iii) Positive culture of dialysate

          3. Age &gt; 18 years old

        Exclusion Criteria:

          1. More than one organism on culture

          2. Contra-indication for systemic thrombolysis (eg. current or recent stroke, major
             haemorrhage or major trauma; proliferative retinopathy; major surgery in the previous
             5 days)

          3. Known sensitivity to DNase or t-PA

          4. Pregnancy or lactating mother

          5. Expected survival less than 3 months

          6. Clinical indication for PD catheter removal, as defined by treating team

          7. Inability to provide written informed consent

          8. Systemic anticoagulation

          9. Severe uncontrolled hypertension

         10. Documented ulcerative gastrointestinal disease during the last three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aron Chakera, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Sir Charles Gairdner Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedland</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Charles Gairdner Hospital</investigator_affiliation>
    <investigator_full_name>Aron Chakera</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis</keyword>
  <keyword>peritoneal dialysis, continuous ambulatory</keyword>
  <keyword>peritonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

